AR092488A1 - Anticuerpos anti-mcam y metodos de uso asociados - Google Patents

Anticuerpos anti-mcam y metodos de uso asociados

Info

Publication number
AR092488A1
AR092488A1 ARP130103202A ARP130103202A AR092488A1 AR 092488 A1 AR092488 A1 AR 092488A1 AR P130103202 A ARP130103202 A AR P130103202A AR P130103202 A ARP130103202 A AR P130103202A AR 092488 A1 AR092488 A1 AR 092488A1
Authority
AR
Argentina
Prior art keywords
mcam
antibodies
associated methods
mcam antibodies
antigen
Prior art date
Application number
ARP130103202A
Other languages
English (en)
Original Assignee
Neotope Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotope Biosciences Ltd filed Critical Neotope Biosciences Ltd
Publication of AR092488A1 publication Critical patent/AR092488A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Prostheses (AREA)
  • Microbiology (AREA)

Abstract

Se describen en la presente anticuerpos anti-MCAM (moléculas de adhesión celular a melanoma) y fragmentos de unión a antígeno de los mismos que son capaces de inhibir la interacción entre MCAM y su ligando, una proteína que comprende una cadena a-4 de laminina. Estos anticuerpos anti-MCAM y fragmentos de unión a antígeno de los mismos pueden ser útiles para, por ejemplo, tratar afecciones inflamatorias caracterizadas por la infiltración de células de expresión de MCAM en un sitio de inflamación en el cuerpo. Composición farmacéutica.
ARP130103202A 2012-09-10 2013-09-09 Anticuerpos anti-mcam y metodos de uso asociados AR092488A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698916P 2012-09-10 2012-09-10
US201261797179P 2012-11-30 2012-11-30
US201261797356P 2012-12-05 2012-12-05

Publications (1)

Publication Number Publication Date
AR092488A1 true AR092488A1 (es) 2015-04-22

Family

ID=50237783

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103202A AR092488A1 (es) 2012-09-10 2013-09-09 Anticuerpos anti-mcam y metodos de uso asociados

Country Status (24)

Country Link
US (6) US20150239980A1 (es)
EP (2) EP3530287A1 (es)
JP (1) JP6339574B2 (es)
KR (1) KR102194568B1 (es)
CN (2) CN107266571A (es)
AR (1) AR092488A1 (es)
AU (2) AU2013312203B2 (es)
CA (1) CA2884463A1 (es)
CL (1) CL2015000582A1 (es)
CO (1) CO7400878A2 (es)
CU (1) CU20150023A7 (es)
DK (1) DK2892562T3 (es)
EA (1) EA201590528A1 (es)
ES (1) ES2718208T3 (es)
HK (1) HK1212256A1 (es)
IL (1) IL237625A0 (es)
MX (1) MX2015002918A (es)
MY (1) MY182427A (es)
PE (1) PE20151286A1 (es)
PH (1) PH12015500514A1 (es)
SG (2) SG10201708127UA (es)
TW (3) TW201922795A (es)
WO (1) WO2014039975A2 (es)
ZA (1) ZA201501858B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
TW201922795A (zh) 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
EP3116911B8 (en) 2014-03-12 2019-10-23 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
TW201623331A (zh) * 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
WO2015136468A1 (en) * 2014-03-13 2015-09-17 Prothena Biosciences Limited Combination treatment for multiple sclerosis
US20170216409A1 (en) * 2014-08-05 2017-08-03 The University Of Chicago Modulation of laminin alpha-4 in the prevention, treatment, and management of metabolic syndromes
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
CN104725483A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 一种黑色素瘤细胞粘附分子拮抗剂多肽及其应用
CN104710513A (zh) * 2015-04-06 2015-06-17 苏州普罗达生物科技有限公司 黑色素瘤细胞粘附分子拮抗剂多肽及其应用
WO2017046774A2 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CA2998716A1 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017100670A1 (en) 2015-12-09 2017-06-15 Corvus Pharmaceuticals, Inc. Humanized anti-cd73 antibodies
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) * 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
WO2018223140A1 (en) * 2017-06-02 2018-12-06 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2019133639A2 (en) * 2017-12-26 2019-07-04 The Regents Of The University Of California Human antibodies that bind and are internalized by mesothelioma and other cancer cells
WO2020132232A2 (en) * 2018-12-21 2020-06-25 Multitude Inc. Antibodies specific to muc18
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1520819A (en) 1976-05-10 1978-08-09 Robertson H J Medical protein hydrolysate process of making the same and processes of utilizing the protein hydrolysate to aid in healing traumatized areas
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
AU757961B2 (en) 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US7192931B2 (en) 2000-10-12 2007-03-20 Neuren Pharmaceuticals Ltd. Treatment of demyelinating diseases
US6866866B1 (en) 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US20030068319A1 (en) 2001-03-23 2003-04-10 Menashe Bar-Eli Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-IL8 and anti-MUC18 in diverse types of tumors
AU2002354784A1 (en) 2001-07-03 2003-01-21 Sciperio, Inc. Methods and systems for embedding electrical components in a device including a frequency responsive structure
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
EP1470146B8 (en) * 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
EP1467756A4 (en) 2001-12-28 2007-03-21 Abgenix Inc METHODS OF USING ANTI-MUC18 ANTIBODIES
CA2472154A1 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Use of antibodies against the muc18 antigen
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
AU2003243651B2 (en) 2002-06-17 2008-10-16 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Specificity grafting of a murine antibody onto a human framework
WO2004001004A2 (en) * 2002-06-21 2003-12-31 Johns Hopkins University School Of Medicine Membrane associated tumor endothelium markers
EP1382615A1 (en) * 2002-07-15 2004-01-21 Xerion Pharmaceuticals AG MCAM inhibitors
MXPA05007823A (es) 2003-01-24 2005-10-18 Elan Pharm Inc Composicion y tratamiento de enfermedades desmielizantes y paralisis por administracion de agentes remielinizantes.
UY28886A1 (es) * 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
KR20070047327A (ko) * 2004-07-26 2007-05-04 비오겐 아이덱 엠에이 아이엔씨. 항-ｃｄ154 항체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2007058725A2 (en) * 2005-10-12 2007-05-24 The Regents Of The University Of California Engineered antibody fragment that irreversibly binds an antigen
JP2009518025A (ja) * 2005-12-06 2009-05-07 ドマンティス リミテッド 細胞表面標的に対して結合特異性を有する二重特異性リガンドおよびその使用方法
WO2009028663A1 (ja) 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
WO2009054435A1 (ja) 2007-10-24 2009-04-30 Otsuka Chemical Co., Ltd. 増強されたエフェクター機能を有するポリペプチド
EP2220122A2 (en) * 2007-11-13 2010-08-25 Teva Biopharmaceuticals USA, Inc. Humanized antibodies against tl1a
CN101896163A (zh) 2007-12-21 2010-11-24 弗·哈夫曼-拉罗切有限公司 抗体制剂
US8155019B2 (en) * 2008-01-07 2012-04-10 Canon Kabushiki Kaisha Information processing apparatus, device information display method, and computer-readable storage medium
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
US8293468B2 (en) * 2009-06-10 2012-10-23 Centre Hospitalier De L'université De Montréal MCAM modulation and uses thereof
EP2460880B1 (en) * 2009-07-29 2014-11-19 Sysmex Corporation Marker and reagent for detection of human il-17-producing helper t cells, and method for detection of human il-17-producing helper t cells
WO2011100477A2 (en) * 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
EP3680253A3 (en) 2010-03-02 2020-09-30 AbbVie Inc. Therapeutic dll4 binding proteins
JP5899213B2 (ja) 2010-08-06 2016-04-06 マイカーティス エヌ．ヴェ．ＭｙＣａｒｔｉｓ ＮＶ 腎機能不全のバイオマーカーとしてのパールカン
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
KR101933084B1 (ko) * 2010-11-25 2018-12-28 알레크라 테라퓨틱스 게엠베하 화합물 및 그의 용도
JP5946605B2 (ja) * 2011-01-28 2016-07-06 シスメックス株式会社 ヒトｉｌ−１７産生ヘルパーｔ細胞の検出方法
JP6305919B2 (ja) * 2011-06-06 2018-04-04 プロセナ バイオサイエンシーズ リミテッド Ｍｃａｍアンタゴニスト及び治療の方法
US10160808B2 (en) 2012-02-16 2018-12-25 Santarus, Inc. Anti-VLA1 (CD49A) antibody pharmaceutical compositions
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
TW201922795A (zh) 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
CN113350278B (zh) 2013-10-24 2023-03-24 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
WO2015136570A1 (ja) 2014-03-11 2015-09-17 パナソニック液晶ディスプレイ株式会社 表示装置及びその駆動方法
US20170101470A1 (en) 2014-03-12 2017-04-13 Prothena Biosciences Limited Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis
US20170129954A1 (en) 2014-03-12 2017-05-11 Prothena Biosciences Limited Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
EP3116911B8 (en) 2014-03-12 2019-10-23 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
CA2938931A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
WO2015136468A1 (en) 2014-03-13 2015-09-17 Prothena Biosciences Limited Combination treatment for multiple sclerosis
CA2998716A1 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018223140A1 (en) 2017-06-02 2018-12-06 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use

Also Published As

Publication number Publication date
DK2892562T3 (en) 2019-04-15
US20140227292A1 (en) 2014-08-14
US20200216560A1 (en) 2020-07-09
US20170037144A1 (en) 2017-02-09
SG11201501773RA (en) 2015-04-29
TW201809001A (zh) 2018-03-16
CN105120895A (zh) 2015-12-02
CL2015000582A1 (es) 2015-11-06
CU20150023A7 (es) 2016-03-31
US9447190B2 (en) 2016-09-20
WO2014039975A3 (en) 2014-06-05
US20170145109A1 (en) 2017-05-25
US20180105602A1 (en) 2018-04-19
US10584177B2 (en) 2020-03-10
WO2014039975A2 (en) 2014-03-13
US10407507B2 (en) 2019-09-10
MX2015002918A (es) 2015-08-14
PE20151286A1 (es) 2015-10-04
MY182427A (en) 2021-01-25
AU2018241135A1 (en) 2018-10-25
US20150239980A1 (en) 2015-08-27
PH12015500514A1 (en) 2015-04-27
TW201422639A (zh) 2014-06-16
US10414825B2 (en) 2019-09-17
CO7400878A2 (es) 2015-09-30
SG10201708127UA (en) 2017-11-29
AU2018241135B2 (en) 2020-04-16
KR20150046350A (ko) 2015-04-29
JP6339574B2 (ja) 2018-06-06
TWI595007B (zh) 2017-08-11
EP2892562B1 (en) 2019-03-06
IL237625A0 (en) 2015-04-30
EP2892562A2 (en) 2015-07-15
ES2718208T3 (es) 2019-06-28
CA2884463A1 (en) 2014-03-13
EP3530287A1 (en) 2019-08-28
HK1212256A1 (en) 2016-06-10
TWI660972B (zh) 2019-06-01
JP2015533795A (ja) 2015-11-26
EP2892562A4 (en) 2016-05-04
TW201922795A (zh) 2019-06-16
AU2013312203A1 (en) 2015-03-19
AU2013312203B2 (en) 2018-07-12
ZA201501858B (en) 2016-11-30
EA201590528A1 (ru) 2015-12-30
CN107266571A (zh) 2017-10-20
KR102194568B1 (ko) 2020-12-28

Similar Documents

Publication Publication Date Title
AR092488A1 (es) Anticuerpos anti-mcam y metodos de uso asociados
CL2012002880A1 (es) Compuestos derivados de pirrolobenzodiazepinas conjugados, entre otros con anticuerpos; procedimiento de preparación de un conjugado; composicion farmaceutica: procedimiento de tratamiento de cancer; y su uso para proporcionar el compuesto a una localizacion diana que es una poblacion celular proliferativa; articulo de fabricacion
DOP2017000053A (es) Derivados de benzodiazepina citotóxicos
NI201500103A (es) Anticuerpos cd47 que no agotan plaquetas ni glóbulos rojos y métodos de uso de los mismos.
DK3430030T3 (da) Transficerede t-celler og t-cellereceptorer til anvendelse i immunoterapi mod cancer
BR112019006865A2 (pt) caspases induzíveis e métodos para uso
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
ECSP11009946A (es) Anticuerpos Anti-CD37
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
BR112015030946A8 (pt) composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
CR20180142A (es) ANTICUERPOS ANTI-FAP Y MÉTODOS DE USO(Divisional Exp: 2013-0038)
AR089993A1 (es) Macrociclos peptidomimeticos
GT201300276A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
ECSP13012786A (es) Anticuerpos anti-pcsk9 y métodos de uso
SV2008002980A (es) Composiciones y metodos de uso para anticuerpos de dickkopf-1 y/0 -4
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
TR201909788T4 (tr) C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri.
UY33647A (es) ?agentes de unión a cd33?.
AR083044A1 (es) Anticuerpos anti-cd48 y usos de los mismos
ECSP11011297A (es) Proteinas ligadoras il-17
GT201400043A (es) Imidazopiridazinas sustituidas con amino
UY32918A (es) Nuevos compuestos de 2-piridona

Legal Events

Date Code Title Description
FB Suspension of granting procedure